Table 1 Characteristics of weight in subjects included in randomized controlled trials evaluating tocilizumab

BACC Bay

Stone [27]

243

8 mg/kg, max 800 mg

BMI = 29.9 (26–34.2) kg/m²

No difference in mechanical ventilation or death

CORIMUNO-19

Hermine [28]

131

8 mg/kg, option for additional 400 mg dose at 72 h

Weight = 80 (70–90) kg

BMI = 27.9 (23.3–30.8) kg/m²

No improvement in need for mechanical ventilation on day 4 or survival free from mechanical ventilation

COVACTA

Rosas [29]

438

8 mg/kg, max 800 mg, option to repeat dose in 8–24 h

Weight = 89 ± 24 kg

No difference in clinical status

COVINTOC

Soin [30]

180

6 mg/kg, max 480 mg, option to repeat dose in 12 h

Not reported

No improvement in progression of disease

EMPACTA

Salama [31]

340

8 mg/kg, max 800 mg, option to repeat dose in 8–24 h

Weight = 90 ± 24 kg

BMI = 32 ± 7.9 kg/m²

Reduction in progression to the composite of mechanical ventilation or death

RCT-TCZ-COVID-19

Salvarani [32]

126

8 mg/kg, max 800 mg followed by 2nd dose after 12 h

BMI ≥ 30 kg/m² = 28%

No difference in clinical worsening

RECOVERY

[33]

1350

800 mg if > 90 kg, 600 mg if > 65 and ≤ 90 kg, 400 mg if > 40 and ≤ 65 kg, 8 mg/kg if ≤ 40 kg, option to repeat dose in 12–24 h

Not reported

Improvement in 28-day survival

REMAP-CAP,

2021 [34]

865

8 mg/kg, max 800 mg, option to repeat dose in 12–24 h

BMI = 30.5 (26.9–34.9) kg/m²

Improvement in respiratory and cardiovascular organ support-free days

REMDACTA

Rosas [35]

649

8 mg/kg, max 800 mg, option to repeat dose in 8–24 h

Weight = 94 ± 27 kg

No difference in time to discharge

TOCIBRAS

Veiga [36]

129

8 mg/kg, max 800 mg

Obesity = 23%

No improvement in clinical status at day 15

Wang [37]

65

400 mg, option to repeat dose at 24 h

Not reported

No difference in cure rate